Drug
Obt076
Obt076: highest development phase Phase 1, developed by Oxford BioTherapeutics Ltd. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Oxford BioTherapeutics Ltd
Trials
| Drug | Phase | Indication |
|---|---|---|
| OBT076, a CD205-directed antibody-drug conjugate NCT04064359 | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Obt076 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.